TD-0903 for ALI Associated With COVID-19

  • STATUS
    Recruiting
  • participants needed
    159
  • sponsor
    Theravance Biopharma
Send
Updated on 5 August 2020
See if I qualify

Summary

This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation.

Details
Condition Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
Age 18years - 80years
Treatment Placebo, TD-0903
Clinical Study IdentifierNCT04402866
SponsorTheravance Biopharma
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Willing and able to provide written informed consent on their own prior to performing study procedures. Subject assent or proxy consent as per local site procedures, may also be acceptable if both a clinician and second health professional attest that the subject understands the risks and potential benefits of the study and elects to proceed. In the event the subject loses capacity during the study, the subject consents to continued participation, except where this is not clinically indicated
Willing and able to comply with study-related procedures/assessments
Age 18 to 80 years old
Febrile ( 37.2C oral or equivalent)
Hospitalized (or documentation of a plan to admit to the hospital if the subject is in an emergency department) and requiring supplemental oxygen to maintain saturation > 90%
Confirmed COVID-19. If testing results are not immediately available, strong clinical suspicion of COVID-19 can be used for inclusion. Testing should still be done in these subjects. Strong clinical suspicion includes
At least 2 of the following
Fever
Cough
Fatigue
Dyspnea
and At least 1 of the following
Radiographic evidence of viral pneumonia
Close contact with a patient who has previously tested positive for COVID-19
Onset of COVID-19 -related symptoms > 2 days and </= 10 days prior to hospital admission

Exclusion Criteria

In the opinion of the investigator, at risk of imminent respiratory failure (i.e., on mechanical ventilation)
Presence or suspicion of active malignancy with the exception of cancer in situ (e.g., skin cancer)
In the opinion of the investigator, unlikely to survive for > 24 hours from enrollment
Women who are pregnant or might be pregnant, or who are currently breast-feeding
Presence of significant comorbidity that, in the opinion of the investigator, predisposes the subject to mortality. Such conditions might include: a. New York Heart Association class IV Heart Failure b. Severe hepatic dysfunction c. Severe renal dysfunction or receiving renal replacement therapy
Presence of septic shock at time of enrollment
Hemoglobin < 80 g/L
Platelets < 5010^9
Hypersensitivity to TD-0903 or its components, or to other JAK inhibitors
Treatment with anti-IL 6, anti-IL-6R antagonists, or with JAK inhibitors in the past 30 days, or plans to receive a JAK inhibitor during the study period
Current treatment with conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs)/immunosuppressive agents including: a. Methotrexate, cyclosporine, mycophenolate, tacrolimus, penicillamine, or sulfasalazine within 2 weeks prior to enrollment b. Azathioprine or cyclophosphamide within 12 weeks prior to enrollment c. Tumor necrosis factor-alpha (TNF)) inhibitors within 12 weeks prior to enrollment
Participating in other clinical trials involving any other experimental treatment for COVID-19, except in the context of a single-arm antiviral compassionate-use protocol
Use of chronic oral corticosteroids for a non-COVID-19-related condition in a dose higher than prednisone 5 mg or equivalent per day
Subjects with active or incompletely treated pulmonary tuberculosis, or known history of non-tuberculosis mycobacterium over past 12 months
Subject requires continuous oxygen supplementation for underlying cardio-respiratory history in the past 90 days
Body Mass Index 40 kg/cm2
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.